Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease
A Cross-sectional Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 4, 2021
- Accepted in final form November 9, 2021
- First Published December 26, 2021.
Author Disclosures
- Rui Li, MD, PhD,
- Thomas Francis Tropea, DO,
- Laura Rosa Baratta, BSc,
- Leah Zuroff, MD, MS,
- Maria E. Diaz-Ortiz, BSc,
- Bo Zhang, MD, PhD,
- Koji Shinoda, MD, PhD,
- Ayman Rezk, PhD,
- Roy N. Alcalay, MD, MS,
- Alice Chen-Plotkin, MD and
- Amit Bar-Or, MD
- Rui Li, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Francis Tropea, DO,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sanofi Genzyme
NONE
NONE
NONE
NONE
(1) NIH/NINDS, K23-NS11416-01A1, PI, 9/2020-6/2025
NONE
(1) Michael J Fox Foundation, (2) Parkinson Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Rosa Baratta, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Leah Zuroff, MD, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria E. Diaz-Ortiz, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bo Zhang, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Koji Shinoda, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ayman Rezk, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roy N. Alcalay, MD, MS,
NONE
NONE
consultation fees from Genzyme/Sanofi, Merck, GSK, Avrobio, Caraway and Ono Therapeutics.
NONE
NONE
NONE
NONE
consultation fees from Genzyme/Sanofi, Janssen, Avrobio and GSK
NONE
NONE
NONE
NONE
NIH, DoD
NONE
1. The Michael J Fox Foundation 2. Parkinson's Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Alice Chen-Plotkin, MD and
NONE
NONE
NONE
NONE
Patents pending on: (1) Viral-mediated gene delivery of the progranulin gene as a therapeutic for frontotemporal dementia (2) Use of the discovery of 8 plasma proteins as biomarkers for diagnostic confirmation of Parkinson's Disease diagnosis (3) Genetic predictor for impulsivity in Parkinson's Disease
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH-NINDS RO1 NS082265 (PI, 2013-2025) (2) NIH-NINDS RO1 NS115139 (PI, 2019-2024) (3) NIH-NIA P30 AG072979 (Project leader, 2021-2026) (4) NIH-NIA U19 AG062418 (PI, 2019-2024)
NONE
(1) Alzheimer's Association/Michael J. Fox Foundation (2) Chan Zuckerberg Initiative Neurodegeneration Challenge (3) AHA/Allen Institute Brain Health Initiative
NONE
NONE
Viral-mediated gene delivery of the progranulin gene as a therapeutic for frontotemporal dementia
NONE
NONE
NONE
- Amit Bar-Or, MD
Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014
(1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -
NONE
NONE
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -
NONE
NONE
NONE
(1) Novartis (2) Genzyme-Sanofi (3) Biogen (4) Merck/EMDSerono (5) Roche/Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the The Center for Neuroinflammation and Neurotherapeutics and the Department of Neurology (R.L., L.Z., K.S., A.R., A.B.-O.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Department of Neurology (T.F.T., L.R.B., M.E.D.-O., A.C-P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Department of Bioengineering (M.E.D.-O.), School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia; Department of Cardiology (B.Z.), the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China; Department of Neurology (R.N.A.), Columbia University, New York, NY.
- Correspondence
Dr. Bar-Or amitbar{at}pennmedicine.upenn.edu or Dr. Chen-Plotkin chenplot{at}pennmedicine.upenn.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.